<DOC>
	<DOCNO>NCT02602327</DOCNO>
	<brief_summary>This phase I dose escalation study ( 3+3 design ) dose expansion arm ( 12 patient ) design evaluate safety combination Tas-102 radioembolization use Yttrium-90 ( 90Y ) resin microspheres patient chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer ( mCRC ) .</brief_summary>
	<brief_title>Tas-102 Radioembolization With 90Y Resin Microspheres Chemo-refractory Colorectal Liver Metastases</brief_title>
	<detailed_description>Randomized study demonstrate Tas-102 single agent activity chemotherapy refractory colorectal cancer . A recent pre-clinical study show Tas-102 may activity radiation sensitizer bladder cancer cell line . Benefit single agent Tas-102 chemotherapy refractory colon cancer drug 's promise radiosensitizer make Tas-102 potential candidate drug test combination radioembolization use Yttrium-90 resin microspheres patient liver-dominant chemotherapy-refractory mCRC . This phase I dose escalation study dose expansion arm design evaluate safety combination Tas-102 radioembolization use 90Y resin microspheres patient chemotherapy-refractory colon rectal adenocarcinoma metastatic liver .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Male female , 18 year age old , ethnic racial group . 2 . Diagnosis unresectable metastatic colorectal adenocarcinoma liverdominant bilobar disease . Diagnosis may make histo cytopathology , clinical imaging criterion . 3 . Disease progression intolerance least two prior Food Drug Administrationapproved therapeutic regimen . 4 . If extrahepatic disease present , must asymptomatic . 5 . If primary tumor place , must asymptomatic . 6 . Measurable target tumor use standard image technique ( RECIST v. 1.1 criterion ) . 7 . Tumor replacement &lt; 50 % total liver volume . 8 . Current Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screen first treatment study . 9 . Completion prior systemic therapy least 14 day prior enrollment . 10 . Able understand inform consent . 1 . At risk hepatic renal failure Serum creatinine &gt; 1.5 mg/dl Serum bilirubin &gt; 1.3 mg/ml Albumin &lt; 2.0 g/dL Aspartate and/or alanine aminotransferase level &gt; 5 time upper normal limit Any history hepatic encephalopathy Cirrhosis portal hypertension Clinically evident ascites ( trace ascites image acceptable ) 2 . Contraindications angiography selective visceral catheterization Any bleeding diathesis coagulopathy correctable usual therapy hemostatic agent ( e.g . closure device ) Severe allergy intolerance contrast agent , narcotic , sedative manage medically 3 . Symptomatic lung disease 4 . Prior therapy Tas102 . 5 . Contraindications Tas102 Absolute neutrophil count &lt; 1,500/μl Platelet count &lt; 75,000/μl Allergy intolerance Tas102 6 . Unresolved toxicity great equal National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade 2 due prior therapy . 7 . Evidence potential delivery Greater 30 Gy absorb dose radiation lung single 90Y resin microsphere administration ; Cumulative delivery radiation lung &gt; 50 Gy multiple treatment . 8 . Evidence detectable Tc99m macro aggregate albumin flow stomach duodenum , application establish angiographic technique stop flow . 9 . Previous radiation therapy lung and/or upper abdomen 10 . Any prior arterial liverdirected therapy , include chemoembolization , bland embolization , 90Y radioembolization 11 . Any intervention , compromise ampulla Vater 12 . Active uncontrolled infection . Presence latent medicationcontrolled HIV and/or viral hepatitis allow . 13 . Significant extrahepatic disease Symptomatic extrahepatic disease ( include primary tumor , unresected ) . Greater 10 pulmonary nodule ( &lt; 10 mm diameter ) combine diameter pulmonary nodule &gt; 80 mm . Peritoneal carcinomatosis 14 . Life expectancy le 3 month 15 . Pregnant lactate female 16 . In investigator 's judgment , comorbid disease condition would place patient undue risk preclude safe use radioembolization Tas102 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>radioembolization</keyword>
	<keyword>Yttrium-90</keyword>
	<keyword>90Y</keyword>
	<keyword>Resin microspheres</keyword>
	<keyword>Tas-102</keyword>
	<keyword>Lonsurf</keyword>
	<keyword>SIR-Sphere</keyword>
</DOC>